HBOT for Wound Healing: Insurance, Medicare, and Getting Covered

Medicare Part B covers hyperbaric oxygen therapy for wound healing when the wound falls within one of 14 CMS-approved indications and the patient has failed at least 30 days of standard wound care. For diabetic foot ulcers (the most common wound indication), coverage requires a Wagner grade III classification or higher. Private insurers generally follow CMS guidelines, though policies vary. Out-of-pocket costs with insurance typically range from $75 to $300 per session in copays, compared to $250-$450 per session without coverage. This is one of several HBOT across various recovery applications gaining attention in clinical practice.

Which Wound Types Does Medicare Cover for HBOT?

The Centers for Medicare and Medicaid Services (CMS) maintains a list of 14 approved conditions for HBOT coverage under the National Coverage Determination (NCD) 20.29. The wound-related indications include:

• Diabetic wounds of the lower extremities (Wagner grade III or higher)
• Chronic refractory osteomyelitis
• Osteoradionecrosis
• Soft tissue radionecrosis
• Necrotizing soft tissue infections (necrotizing fasciitis, gas gangrene)
• Compromised skin grafts and flaps
• Crush injuries and suturing of severed limbs
• Acute peripheral arterial insufficiency
• Preparation and preservation of compromised skin grafts

Each indication has specific clinical criteria that must be documented before coverage is approved. The burden of documentation falls on the treating physician and the hyperbaric facility. Incomplete or poorly organized documentation is the single most common reason for coverage denials.

The 30-Day Standard Care Requirement

Medicare does not cover HBOT as a first-line wound treatment. Before approving hyperbaric sessions, CMS requires documentation showing that the patient received at least 30 consecutive days of standard wound care without adequate improvement. Standard care must include:

• Assessment and optimization of nutritional status (albumin, pre-albumin levels documented)
• Glucose optimization for diabetic patients (target HbA1c below 8%, or documented efforts to achieve it)
• Debridement of necrotic tissue (sharp, enzymatic, or autolytic, as clinically appropriate)
• Moist wound management with appropriate dressings (changed per manufacturer guidelines)
• Offloading for lower-extremity wounds (total contact casting, removable cast walkers, or therapeutic footwear)
• Treatment of active infections with culture-guided antibiotics
• Adequate vascular assessment (ABI, toe pressures, or arterial duplex) and revascularization if indicated
• Tobacco cessation counseling for active smokers

“Failure to improve” means the wound has not decreased in size by at least 15% over the 30-day standard care period, as measured by length x width wound area calculations. This measurement must be documented with standardized wound measurement techniques (ruler, planimetry, or digital photography with scale markers). Eyeball estimates are not sufficient for CMS documentation.

This requirement exists because many chronic wounds will respond to optimized standard care alone, and HBOT should be reserved for those that genuinely need adjunctive therapy. Studies show that 30-50% of diabetic foot ulcers that seem “non-healing” will actually respond when standard wound care is properly optimized.

Wagner Grade Requirements for Diabetic Wounds

The Wagner classification system grades diabetic foot ulcers from 0 to 5 based on wound depth and the presence of infection or gangrene:

• Grade 0: Pre-ulcerative lesion, healed ulcers, bony deformity
• Grade I: Superficial ulcer, skin only
• Grade II: Deep ulcer reaching tendon, bone, or joint capsule
• Grade III: Deep ulcer with abscess, osteomyelitis, or joint sepsis
• Grade IV: Localized gangrene (forefoot or heel)
• Grade V: Extensive gangrene requiring major limb amputation

Medicare covers HBOT only for Wagner grade III and above. This means the ulcer must extend beyond superficial tissue into deeper structures with evidence of infection or tissue death. Grade I and II ulcers, while potentially serious, are expected to respond to standard wound care and are not covered for HBOT under CMS policy.

There is clinical debate about whether this threshold is too restrictive. Some hyperbaric medicine specialists argue that earlier intervention at Wagner grade II (before osteomyelitis develops) would improve outcomes and reduce total healthcare costs. However, CMS has not modified the requirement, and appeals based on Wagner II classification are rarely successful.

Your wound care team should document the Wagner grade clearly in your medical record, supported by physical examination findings, imaging (MRI for osteomyelitis, X-ray for bony changes), and laboratory data (ESR, CRP, bone biopsy results if available). If you believe your wound qualifies but has been classified at a lower grade, request a reassessment with imaging. Our DFU data page covers the clinical outcomes by Wagner grade.

Prior Authorization: What to Expect

Most private insurers and Medicare Advantage plans require prior authorization before HBOT begins. Original Medicare (Parts A and B) does not require formal prior authorization, but the treating facility must verify that the patient meets coverage criteria before starting treatment. The authorization process for private insurers typically involves submitting:

• Clinical notes documenting the wound type, size, duration, and classification
• Evidence of 30 days of failed standard wound care with serial wound measurements
• Transcutaneous oximetry (TCOM) results showing wound-area hypoxia
• Photographs of the wound at baseline and after 30 days of standard care
• A treatment plan specifying the number of sessions requested (usually 20-40)
• Wagner grade classification (for diabetic wounds) with supporting imaging
• Vascular assessment documentation (ABI, toe pressures)

Authorization decisions typically take 5-15 business days. Some insurers offer expedited review for urgent cases (compromised grafts, necrotizing infections) within 24-72 hours. Denials are common on first submission, particularly if documentation is incomplete or if the medical reviewer is unfamiliar with HBOT indications.

Working with a wound care center experienced in HBOT billing significantly improves approval rates. Many hyperbaric facilities have dedicated insurance coordinators who handle the prior authorization process and know exactly which documentation each payer requires. Facilities that bill Medicare for HBOT regularly have denial rates of 10-15%, compared to 30-40% at facilities that rarely provide the service.

CPT Codes and Billing for HBOT Wound Care

HBOT billing uses specific CPT (Current Procedural Terminology) codes that determine reimbursement rates. The primary codes are:

• CPT 99183: Physician supervision of hyperbaric oxygen therapy, per session. This covers physician attendance and monitoring during the treatment. The physician must be physically present in the facility (not just on call) and must evaluate the patient before each session.
• HCPCS G0277: Hyperbaric oxygen therapy, full body chamber, per 30-minute interval. This is the facility fee for operating the chamber. A 90-minute session = 3 units of G0277. A 120-minute session = 4 units.

Medicare reimburses approximately $74-$116 for CPT 99183 (physician component) and $82-$126 per unit of G0277 (facility component), though rates vary by geographic region and facility type (hospital outpatient vs. freestanding clinic). For a standard 90-minute session, total Medicare reimbursement to the facility is typically $320-$500.

The patient’s 20% Medicare Part B coinsurance means an out-of-pocket cost of roughly $64-$100 per session after the annual deductible ($240 in 2024) is met. Over a 40-session treatment course, total patient out-of-pocket under Original Medicare is approximately $2,500-$4,000. Patients with Medigap supplemental insurance (Plan C, F, or G) may have their coinsurance covered, reducing out-of-pocket costs further.

For a detailed breakdown of HBOT billing codes across all indications, see our CPT codes and billing guide.

Private Insurance Coverage: How It Varies

Most major private insurers (Blue Cross Blue Shield, Aetna, UnitedHealthcare, Cigna, Humana) cover HBOT for CMS-approved wound indications when clinical criteria are met. However, coverage details differ significantly between carriers and even between plans within the same carrier.

Aetna covers HBOT for diabetic wounds of the lower extremity (Wagner III+), chronic refractory osteomyelitis, compromised grafts/flaps, necrotizing infections, and radiation injuries. Their clinical policy bulletin (CPB 0172) requires TCOM testing and prior authorization. Aetna considers HBOT experimental for venous leg ulcers and pressure ulcers.

UnitedHealthcare follows CMS guidelines closely and requires documented failure of 30 days of standard care. They often request re-authorization after the initial 20 sessions and may require a physician peer-to-peer review to justify continued treatment.

Blue Cross Blue Shield policies vary by state affiliate. Most cover the standard CMS wound indications but may impose session limits (commonly 40-60 per wound episode). Some BCBS affiliates have adopted stricter criteria than CMS, requiring TCOM documentation even for indications where CMS does not mandate it.

Cigna covers HBOT for approved wound indications under their medical coverage policy. They require prior authorization and limit initial authorizations to 20 sessions, with re-authorization required for extensions.

Always call the number on your insurance card and ask specifically about HBOT (CPT 99183 and HCPCS G0277) for your diagnosed wound type. Get the authorization reference number in writing. Verbal confirmations are not binding. Our HBOT insurance overview covers strategies for appealing denials.

What You Will Pay Out of Pocket

Even with insurance approval, HBOT involves significant cost-sharing. Here is what patients typically pay across different coverage scenarios:

With Medicare Part B (Original Medicare): 20% coinsurance after the annual deductible ($240 in 2024). For a 40-session protocol, total out-of-pocket is approximately $2,500-$4,000 depending on your geographic region. If you have a Medigap supplemental plan (Plan G is the most common new enrollment plan), the supplement covers most or all of the 20% coinsurance, potentially reducing your cost to just the Part B deductible.

With Medicare Advantage: Copays and coinsurance structures vary by plan. Some MA plans charge a flat copay per HBOT session ($50-$150), while others apply specialist coinsurance (20-30%). MA plans may also require use of in-network facilities, which could limit your choice of hyperbaric centers.

With private insurance (employer-sponsored): Copays range from $50 to $300 per session depending on your plan’s cost-sharing structure. Many plans apply HBOT to the specialist copay or outpatient procedure tier. A 40-session protocol with a $75 copay totals $3,000 out of pocket. High-deductible health plans (HDHPs) require meeting the full deductible first ($1,600-$3,200 individual in 2024), after which coinsurance applies.

Without insurance: Cash-pay rates for clinical HBOT range from $250 to $450 per session at hospital-based wound centers, and $150 to $350 at freestanding clinics. A full 40-session wound protocol without insurance can cost $10,000 to $18,000. Some facilities offer package discounts (10-20% off for prepaid multi-session packages) or payment plans. See our HBOT cost guide for a full pricing breakdown.

Medicare Advantage and Medicaid

Medicare Advantage (Part C) plans must cover everything Original Medicare covers, including HBOT for approved wound indications. However, Medicare Advantage plans can impose stricter prior authorization requirements, limit you to in-network facilities, and require step therapy documentation beyond what Original Medicare demands. If your MA plan denies HBOT coverage for a CMS-approved indication, you have the right to appeal through the MA plan’s internal process and, if necessary, to an independent review organization.

Medicaid HBOT coverage varies by state. As of 2024, most state Medicaid programs cover HBOT for CMS-approved wound indications, but prior authorization requirements and session limits differ substantially. Some states limit Medicaid HBOT to hospital-based wound centers only, excluding freestanding clinics. Dual-eligible patients (those with both Medicare and Medicaid) typically have their Medicare coinsurance and deductible covered by Medicaid, making HBOT essentially free at the point of service.

Veterans Affairs (VA) medical centers provide HBOT for approved wound indications at no cost to eligible veterans. The VA operates hyperbaric medicine programs at multiple facilities nationwide. Wait times for VA HBOT can be significant (4-8 weeks in some locations), so veterans with urgent wound care needs should also explore community care referral options under the MISSION Act.

What to Do If Your Claim Is Denied

HBOT claim denials are common, especially on first submission. Data from hyperbaric medicine billing organizations suggests that 25-35% of initial HBOT authorizations are denied, but approximately 60-70% of denials are overturned on appeal. The most frequent denial reasons include:

• Incomplete documentation of the 30-day standard care period
• Missing or inadequate TCOM results
• Wound classified below the required grade (Wagner II instead of III)
• Lack of evidence that standard care actually failed (no serial wound measurements)
• Treatment facility not in network
• Medical necessity not established (insufficient clinical notes)

If denied, request the specific reason in writing. Most denials can be overturned on appeal with additional documentation. Key steps include:

Level 1 (Internal appeal): Submit additional clinical documentation addressing the specific denial reason. Include peer-reviewed literature supporting HBOT for your wound type, UHMS clinical practice guidelines, and any additional wound measurements or photographs. Your hyperbaric physician should write a letter of medical necessity explaining why HBOT is required for your specific clinical situation.

Level 2 (Peer-to-peer review): Request that your wound care physician speak directly with the insurer’s medical director. This is often the most effective step, because denial decisions are frequently made by reviewers unfamiliar with hyperbaric medicine. A direct physician-to-physician conversation allows your doctor to explain the clinical rationale in detail.

Level 3 (External review): If internal appeals are exhausted, you have the right to request an independent review organization (IRO) evaluation. The IRO assigns a physician reviewer with relevant specialty expertise to evaluate your case independently. External reviews overturn approximately 40-50% of HBOT denials according to industry data from the Baromedical Nurses Association.

Throughout the appeals process, do not discontinue wound care. Continue standard wound management while the appeal is pending, and document any wound deterioration that occurs during the delay. Progressive wound worsening during the appeals process strengthens your case for medical necessity.

Seph Fontane Pennock

Author

Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.

Website